ClinicalTrials.gg
Not yet recruitingNCT06835790HH-N SleeveUpdated Feb 19, 2025

Comparative 3-year Study of Nissen-sleeve vs. Sleeve Plus Cruroplasty in Obese Patients With Hiatal Hernia

An interventional study of Ph-measurement and Questionnaires in Obesity and Hiatal Hernia, sponsored by Elsan. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Elsan · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The success of laparoscopic sleeve gastrectomy (LSG) is not only due to its proven efficacy in the treatment of obesity and associated to comorbidities in the short and long term, but also because it is considered as less technically complicated compared to other malabsorptive procedures. Unfortunately, the main long-term side effect of LSG appears to be the development of severe gastroesophageal reflux (GERD). This problem is aggravated by the concomitant presence of a hiatal hernia at the time of surgery. Indeed, by causing laxity of the lower esophageal sphincter (LES), the hiatal hernia reduces the barrier functions of the esophageal-gastric junction against the reflux of gastric contents.

The classic combination of sleeve and hiatal hernia treatment by cruroplasty gives contradictory results and several surgeons prefer to perform only the sleeve without addressing the hiatal hernia especially if it is small (\<4 cm). For this reason a modification of the usual surgical technique of LSG has been proposed by adding a Nissen fundoplication-Nissen Sleeve (NS). The intentions of this technique were to minimize the rate of postoperative GERD especially for patients with hiatal hernia, to protect the staple line of the angle of His, and finally to provide a safe and effective alternative for patients with a contraindication to LRYGB due to GERD. Although the first results of the technique are encouraging, the realization of the Nissen valve remains a sensitive technical point that can transform a relatively simple procedure like LSG into a more complex procedure like NS. The only test able to directly identify and classify gastric reflux is pH-metry with or without esophageal manometry. Unfortunately, especially due to the difficulty of access to the examination, there are no studies with solid scientific bases that identify the correct conduct to adopt in the case of an obese patient with a hiatal hernia (with or without preoperative reflux).

The main objective of this study is to evaluate the occurence or worsening of GERD at 3 years following a Nissen-sleeve vs. sleeve plus cruroplasty intervention in patients with obesity and hiatal hernia.

02

Conditions studied

  • Obesity
  • Hiatal Hernia
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 150 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Elsan is the lead sponsor of 68 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient,
  • Patient with severe obesity ( >35) with comorbidity or morbidity (BMI >40),
  • Patient awaiting a sleeve gastrectomy,
  • Patient with a hiatal hernia \<or= 4 cm,
  • Patient having undergone a gastroscopy,
  • Patient having undergone an esophagogastroduodenal transit (OGDT),
  • Patient having been informed and having given their free, informed and written consent,
  • Patient affiliated with or beneficiary of a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Patient with poorly controlled diabetes,
  • Patient with major esophageal motility disorders,
  • Patient with a Hiatal Hernia > 4cm,
  • History of bariatric surgery, history of ring,
  • Patient refusing pH-metry examination,
  • Refusal to participate in the study,
  • Patient under legal protection,
  • Patient not benefiting from health protection,
  • Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Nissen sleeve surgery

    Diagnostic Test: Ph-measurement · Other: Questionnaires · Diagnostic Test: gastroduodenal transit

  • Active comparator
    Sleeve plus cruroplasty

    Diagnostic Test: Ph-measurement · Other: Questionnaires · Diagnostic Test: gastroduodenal transit

Interventions

  • Diagnostic testPh-measurement

    Ph measurement before and after the surgery

  • OtherQuestionnaires

    GERD-HRQL Reflux symptom index scale before and after surgery

  • Diagnostic testgastroduodenal transit

    Imaging test that uses the properties of X-rays - after the administration of a radiopaque contrast agent (usually barium) - to visualize the upper digestive tract: the esophagus, stomach, and duodenum (the upper segment of the small intestine).

06

What researchers measure

Primary outcomes

  1. Appearance of GERD 3 years after surgery.

    Occurrence if DeMeester score at 3 years is ≥ 14.72 (\<14.72 before surgery) and/or treatment with proton pump inhibitors (PPIs) and/or Reflux Disease Questionnaire score \> 10 (≤10 before surgery) and/or GERD-HRQL score \> 16 (≤16 before surgery).

    Time frame: 3 years

  2. Worsening of GERD 3 years after surgery.

    Worsening if increase in DeMeester score at 3 years compared to that before the intervention and/or introduction or increase in the dose of PPI compared to that before the intervention and/or increase in the Reflux Disease Questionnaire score at 3 years compared to that before the intervention and/or increase in the GERD-HRQL score at 3 years compared to that before the intervention.

    Time frame: 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Nov 2028, 44 months later.

Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.

Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 19, 2025
StartEst.
Mar 2, 2025
Primary completionEst.
Nov 2, 2028
CompletionEst.
Nov 2, 2031
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06835790
Lead sponsor
Elsan
Collaborators
Clinique saint-Michel de Toulon
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Mar 2, 2025 (estimated)
Primary completion
Nov 2, 2028 (estimated)
Completion
Nov 2, 2031 (estimated)
Last update
Feb 19, 2025

Study contacts

Sergio D Carandina
Contact
sergio.carandina@gmail.com
00334 94 03 96 20

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion